Purchase 5-MeO-pyr-T
Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 5-MeO-pyr-T for sale
5-MeO-pyr-T, 5-methoxy-N, N-tetramethylenetryptamine is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T. 5-MeO-pyr-T was first synthesized by Hunt & Brimblecombe, who credited S. Mitzal for the characterization of chemical properties. Later human tests were reported by Alexander Shulgin in his book TiHKAL. An oral dosage of 0.5 to 2 mg and an inhaled dosage of 2–3 mg are reported.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T. 5-MeO-pyr-T was first synthesized by Hunt & Brimblecombe, who credited S. Mitzal for the characterization of chemical properties. Later human tests were reported by Alexander Shulgin in his book TiHKAL.
5-methoxy-N, N-tetramethylenetryptamine (5-MeO-pyr-T or 5-MeO-pyran) is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T. It was first synthesized by Hunt & Brimblecombe, who credited S. Mitzal for the characterization of chemical properties. Alexander Shulgin reported further human tests in his book TiHKAL.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T.
5-methoxy-N, N-tetramethylenetryptamine, known more commonly as 5-MeO-pyr-T, is a lesser-known psychedelic chemical of the tryptamine class.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a lesser-known psychedelic drug related to tryptamines. 5-MeO-pyr -T was first discovered in the 1960s by Barger & Hough in the United Kingdom. Shulgin also reported that 5-MeO-pyr -T was first synthesized by Hunt & Brimblecombe.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It was first synthesized by Hunt & Brimblecombe and then discovered by Barger & Hough. It was also first reported by Shulgin.
5-MeO-pyr -T is a lesser-known psychedelic drug sold on the internet as a "research chemical." 5-MeO-pyr -T was first discovered in the 1960s by Barger & Hough in the United Kingdom, in whom it was described as having psychedelic effects. Shulgin also reported that 5-MeO-pyr -T was first synthesized by Hunt & Brimblecombe.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a lesser-known psychedelic substance of the tryptamine class. It produces its psychedelic effects through its activity at the 5-HT 2A receptor as an agonist.
5-MeO-pyr-T is a lesser-known psychedelic substance of the tryptamine class. It is similar in structure to other psychedelic substances such as psilocybin, 4-AcO-DMT and DMT, and produces its psychedelic effects through its activity at the 5-HT 2A receptor as an agonist.
5-MeO-pyr-T (5-methoxy-N, N-tetramethylenetryptamine) is a psychedelic drug that can potentially cause psychedelic effects. The psychoactive effects of 5-MeO-pyr-T are believed to come from its efficacy at the 5HT2A receptor as a partial agonist.
5-MeO-pyr-T is a psychedelic substance of the tryptamine class. It produces its psychedelic effects through its activity at the 5-HT 2A receptor as an agonist.
5-methoxy N, N-tetramethylenetryptamine (5-MeO-pyr-T) is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
100mg $840
500g $1390
100g $390
out of stock
100mg $840
100g $490
500g $1390
-min-200x127.JPG)
100g $550
1kg $1590
1kg $1590
200g $690